DEVELOPING MEDICINES FOR COMPANION ANIMALS IN THE EU

3, 4, 5 & 6 February 2014, Conf. No V2-8314



Registration oformation

Application to Register Please PRINT your details: Title First Name..... (Dr. Mr. Mrs. etc) Family name Position Department..... Company Company VAT No. Address City Post Code Country..... Tel No. Fax No. E-mail Secretary's Name Payment by either: VISA MASTERCARD AMEX Card No Card Security No.

Expiry date...../....

Cheque enclosed payable to Management Forum Limited

Bank transfer on receipt of invoice

+44 (0) 1483 730008



Management Forum Ltd \searrow Õ www.management-forum.co.uk

E-mail: registrations@management-forum.co.uk

If you have NOT received confirmation seven days after registering, please contact Registration Department.



Conference Dinner 4 February 2014 Start: 09.00 - Finish: 17.00 5 February 2014 Start: 09.00 - Finish: 17.00 6 February 2014 Start: 09.00 - Finish: 12.30 **Registration & Coffee** 09.00

3 February 2014

Dates

3 February 2014

Venue and Accommodation The Rembrandt Hotel, 11 Thurloe Place, London SW7 2RS Hotel Tel: +44(0)20 7589 8100 Hotel Fax:+44(0)20 7225 3476 Email: reservations_rembrandt@sarova.co.uk Subject to availability, a limited number of bedrooms have been reserved at the hotel at a special rate. All bookings should be made directly with the hotel or online at www.sarova.com/rembrandt, quoting promo code 'manforum'.

Directions

Opposite V&A Museum. Nearest underground station: South Kensington. www.sarova-rembrandthotel.com/location-local-attractions

Fee

£2,000 + VAT if applicable. The fee includes course documentation as well as mid-session refreshments, lunch and conference dinner. Invoice and confirmation will be forwarded to you.

Conference No. V2-8314

Discounted Rates

Available on application for personnel from non-profit making organisations and registered charities. Group discount available on request

Cancellation Policy:

Over 14 days prior to the Seminar: Cancellation fee of £75. 7/14 days prior to the Seminar: 50% of the fee. Fewer than 7 days or if no notification received: Registrant liable to pay FULL seminar fee. NB: Cancellations must be received in writing by registrations@management-forum.co.uk Management Forum reserves the right to cancel/alter the programme, the speakers. the date or venue. If an event is cancelled Management Forum is not responsible for airfare, hotel or other costs incurred by registered delegates.

For Promotional Opportunities email: robert@management-forum.co.uk

If you do not want to receive future mailings from Management Forum please contact nick@management-forum.co.uk If you do not wish to receive selected third party mailings please contact nick@management-forum.co.uk

MANAGEMENT FORUM LTD, 98-100 Maybury Road, Woking, Surrey GU21 5JL, UK Tel: +44 (0)1483 730071 Fax: +44 (0)1483 730008 Website: www.management-forum.co.uk



Updated Programme

DEVELOPING MEDICINES FOR COMPANION **ANIMALS IN THE EU**

Key topics to be covered on this course:

- EU Regulatory Framework
- Product Development
- Process Scale Up and Validation
- How to 'Block Out Studies'
- Part III: the **Toxicological Package**
- User Safety: Risk Assessment
- Environmental Risk Assessment

- Pre-Clinical **Development**
- Clinical Trial Applications
- **Clinical Development**
- **Target Species** Tolerance
- Minor Use and Minor Species (MUMS)
- Regulatory Strategies and Procedures
- Writing the Regulatory Submission

Chairman:

Ray Harding, Consultant

Tutors:



Julian Braidwood, Managing Director, Triveritas Ltd Dr Raymond Munden, Pharmaceutical Consultant

Linkedin

facebook

You can register online at www.management-forum.co.uk or by phone on +44 (0)1483 730071, fax 730008



3, 4, 5 & 6 February 2014 The Rembrandt Hotel, London



INTRODUCTION AND OBJECTIVES

The development of a veterinary medicine is complex, time consuming and expensive. It requires teamwork from individuals with different scientific training and a wide range of skills. Everyone involved must be aware of the main stages in the development programme and be able to relate his or her responsibilities to the expertise and needs of the scientists and commercial members of the team.

This course has been designed to demonstrate how pharmaceutical, pharmacological, toxicological and clinical investigations and regulatory management are brought together in the development programme. It will take the participants through all of the stages in the development of a veterinary medicinal product for companion animals, for which a marketing authorisation is sought in the European Union. Presentations will cover pharmaceutical and process development, toxicological, pharmacological, safety risk assessments, clinical development, and regulatory submissions. An important part of the course will be devoted to working on case studies in the workshop sessions.

The course will provide a comprehensive introduction to the entire development programme for companion animal medicines.

WHO SHOULD ATTEND

The course has been designed for anyone who has limited experience in only one of the disciplines in veterinary medicine development, such as pharmaceutical or analytical development, clinical trials, regulatory affairs or quality assurance. Anyone learning the role of project manager, as well as more experienced personnel seeking to review special problems encountered in product development, will benefit from the comprehensive programme delivered by experienced professionals. There will be ample opportunity for informal discussion during the proceedings.

If possible please bring a laptop with you to use during the workshop sessions.

CHAIRMAN

Ray Harding, Consultant, has worked in the veterinary pharmaceutical industry since 1979 and was previously employed by Glaxo, Pitman Moore and Rhône Mérieux. He established the team at Cyton Biosciences Ltd in 1997 to provide specialist services in new product development and registration for the bioscience industries in Europe. After managing Cyton since it was founded he left the company in 2012 and has taken the role of independent consultant.

TUTORS

Julian Braidwood is Managing Director of Triveritas which is a contract product development company offering a comprehensive range of services to the Animal Health industry and related companies.

Toxicological studies

Led by Ray Harding

· Clinical studies

19.30 Conference Dinner at a

Local Restaurant

17.15 End of Day One

· Pharmacokinetic studies

Dr Raymond Munden has over 30 years experience in pharmaceutical research and development and was formerly Head of Analytical Services Europe for GlaxoSmithKline.

DOCUMENTATION

Delegates will receive a course material folder containing comprehensive documentation provided by the speakers, which will be a valuable source of reference for the future

Day One 3 February 2014 Day Two 4 February 2014 Day Three **SESSION ONE: TUTOR - RAY HARDING SESSION THREE: TUTOR – RAY HARDING** SE 09. 09.30 Introduction and Objectives 09.00 Part III: The Toxicological Package The objective of Part III of the Course PROGRAMME The data required OGRAMM 09.45 EU Regulatory Framework · Understanding the regulatory objectives 09.45 User Safety: Risk Assessment • EU legal framework Reviewing toxicology studies Legal base of regulatory procedures Setting the scenario P,R and dossier requirements Risk assessment · Risk management 10. 10.30 Coffee 11. 10.15 Pharmacokinetics and Bioequivalence 10.45 EU Regulatory Framework...continued Role of pharmacokinetic studies in product development 11.30 Assessing Development Candidates Bioequivalence studies 11.4 New chemical entities and older products · Exemptions from bioequivalence studies 11.45 Project Team: R&D and Marketing 11.00 **Coffee** · Defining marketing objectives 12. · Costs and profitability 11.15 Environmental Risk Assessment The Project Manager and Project Team SE Phase I Assessment 12.15 Discussion 13. 11.30 Introduction to Workshop 15. 12.30 Lunch Objectives of the workshop and review case studies 15. SESSION TWO: TUTOR - DR RAYMOND MUNDEN Planning approach to workshop and workshop teams 13.30 **Product Development** · Physical and chemical characteristics of the 12.30 Lunch drug substance Day Four Process development **SESSION FOUR: TUTOR - RAY HARDING** · Requisites of an ideal product Formulation development 13.30 Workshop Session Requirements of different formulation types 15.15 **Tea** 15.15 **Tea** 15.30 Product Development....continued 15.30 Planning Pre-Clinical and Clinical Optimising performance of problem drug 10.45 Coffee Development substances · Preparing pilot batches Analytical development and setting PKs and target animal tolerance specifications Approaches to dose selection Stability testing · Clinical trial applications Transfer to production 16.30 Workshop: Understanding How to 16.00 EU Regulatory Strategies and "Block Out Studies" Procedures · Pharmaceutical studies

- Full and abbreviated applications
 - Generic applications
 - Centralised Procedure
 - Decentralised, MRP and National Procedures

17.00 End of Day Two

.,	••••••••••••••••••••••••••••••••••••••	
SSION FIVE: TUTOR – JULIAN BRAIDWOOD		
• Selec • Field - M - C - R - B	al Development ting a dose studies lulti-centred controlled tandomised linded acy guidelines	
.30 🕨 Coffee		
	Species Tolerance guideline safety	
WhatWhat	Use and Minor Species (MUMS) are minor species? are minor uses? waches to preparation of clinical data	
.30 ► Lunch	: TUTOR - RAY HARDING	
.30 ▶ Final V .00 ▶ Tea	Vorkshop Session	
.15 🕨 Final V	Norkshop Session (continued)	

17.00 End of Day Three

6 February 2014

ROGRAM

SESSION SEVEN: TUTOR – RAY HARDING

- 09.00 Workshop Presentations
 - Presentation by each team
 - Review and discussion of each presentation

11.15 Writing and Managing the EU **Regulatory Submission**

- Seeking Scientific Advice
- Writing the Marketing Authorisation Application
- Summary of Product Characteristics and labelling
- Working with Writers on Detailed and Critical Summaries in the EU
- Pre-submission Advice and Oral Hearings
- 12.00 Concluding Remarks
- 12.30 End of Course and Lunch

A Certificate of Attendance for Professional Development will be given to each participant who completes the course

5 February 2014